CCM® therapy is covered by Medicare

Medicare and Medicare Advantage cover CCM® therapy for FDA-indicated patients aged 18 or older who have not undergone a heart transplant.
Click here for more information
  • Home
  • Patients
    • Causes
    • Symptoms
    • Diagnosis
    • Treatment
    • Patient Stories
  • Providers
    • Indications & Patient Selection
    • Procedure and Mode of Action
    • Heart Failure Resources
    • Reimbursement
    • Instructions for Use and Product Manuals
  • Our Science
    • Clinical Studies
      • Aim Higher Study
      • Integra-D
    • Publications
  • Company
    • Executive Team
    • News Center
    • Safety Information
    • Ethics & Compliance
    • Grants & Donations
    • Careers
    • Contact Us
  • Find A Provider
  • REGION
    • North America
      • United States
      • Pacific
      • Australia
      • New Zeland
    • Pacific
      • Australia
      • New Zeland
    • Europe
      • Austria
      • Belgium
      • Czech Republic
      • Denmark
      • Finland
      • France
    • Europe
      • Germany
      • Hungary
      • Ireland
      • Italy
      • Netherlands
      • Norway
    • Europe
      • Poland
      • Portugal
      • Spain
      • Sweden
  • Home
  • Patients
    • Causes
    • Symptoms
    • Diagnosis
    • Treatment
    • Patient Stories
  • Providers
    • Indications & Patient Selection
    • Procedure and Mode of Action
    • Heart Failure Resources
    • Reimbursement
    • Instructions for Use and Product Manuals
  • Our Science
    • Clinical Studies
      • Aim Higher Study
      • Integra-D
    • Publications
  • Company
    • Executive Team
    • News Center
    • Safety Information
    • Ethics & Compliance
    • Grants & Donations
    • Careers
    • Contact Us
  • Find A Provider
  • REGION
    • North America
      • United States
      • Pacific
      • Australia
      • New Zeland
    • Pacific
      • Australia
      • New Zeland
    • Europe
      • Austria
      • Belgium
      • Czech Republic
      • Denmark
      • Finland
      • France
    • Europe
      • Germany
      • Hungary
      • Ireland
      • Italy
      • Netherlands
      • Norway
    • Europe
      • Poland
      • Portugal
      • Spain
      • Sweden

Global Regulatory Organization Certifies Optimizer Smart Device as Compliant for Whole-Body MRI Scans in the EU

by Impulse Dynamics | Feb 16, 2021 | News and Events, Press Releases

NEWS GLOBAL REGULATORY ORGANIZATION CERTIFIES OPTIMIZER SMART DEVICE AS COMPLIANT FOR WHOLE-BODY MRI SCANS IN THE EU Impulse Dynamics Receives Medical Device Approval for European Union to Safely Administer MRI Scans for Heart Failure Patients with Implanted Optimizer...

Impulse Dynamics Announces FDA Approval for Magnetic Resonance Imaging

by Impulse Dynamics | Jan 20, 2021 | News and Events, Press Releases

NEWS IMPULSE DYNAMICS ANNOUNCES FDA APPROVAL FOR MAGNETICRESONANCE IMAGING FDA Clears Potential Hurdle for Many Heart Failure Patients MARLTON, N.J., January 20, 2021 — Impulse Dynamics, a company dedicated to improving the lives of people with heart failure (HF),...

Impulse Dynamics Closes $60 Million Financing

by Impulse Dynamics | Jan 12, 2021 | News and Events, Press Releases

NEWS IMPULSE DYNAMICS CLOSES $60 MILLION FINANCING Funding to Accelerate Clinical and Product Development Pipelines, Commercialization of Optimizer Smart System for Heart Failure MARLTON, N.J., January 12, 2021 — Impulse Dynamics, a company dedicated to helping...

Impulse Dynamics Announces First Heart Failure Patient Treated with CCM Therapy in Brazil

by Impulse Dynamics | Jan 5, 2021 | Press Releases

NEWS Impulse Dynamics Announces First Heart Failure Patient Treated with CCM Therapy in Brazil Breakthrough Therapy Now Commercially Available in South America’s Most Populous Country MARLTON, N.J. – January 05, 2021 – Impulse Dynamics, a company dedicated to helping...

Impulse Dynamics Announces Publication of Data from FIX-HF-5C2 Study Evaluating the Two-Lead Optimizer System

by Impulse Dynamics | Apr 14, 2020 | Press Releases

NEWS Impulse Dynamics Announces Publication of Data from FIX-HF-5C2 Study Evaluating the Two-Lead Optimizer System Availability of the two-lead device represents a significant advancement in the development of cardiac contractility modulation therapy for patients with...
« Older Entries
Next Entries »

Recent Posts

  • Impulse Dynamics Announces 100th Implant Milestone in China for CCM® Therapy
  • Impulse Dynamics Announces First International Implants of the Optimizer Smart Mini System in Italy
  • Late-breaking Results Show Efficacy for CCM in Patients With HFpEF
  • IMPULSE DYNAMICS COMPLETES $101M FINANCING ROUND
  • IMPULSE DYNAMICS ANNOUNCES FIRST IMPLANTS OF OPTIMIZER SMART MINI

Recent Comments

    Archives

    • November 2022
    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • January 2022
    • November 2021
    • October 2021
    • July 2021
    • February 2021
    • January 2021
    • April 2020
    • March 2020
    • December 2019
    • November 2019
    • October 2019
    • July 2019
    • March 2019
    • May 2018
    • December 2017
    • August 2017
    • May 2017
    • March 2017
    • September 2016
    • May 2016
    • March 2016
    • January 2016
    • November 2015
    • August 2015
    • July 2015
    • January 2015
    • December 2014

    Categories

    • News and Events
    • Press Releases

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org